Aclaris Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$3.75(as of Mar 19, 3:51 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Aclaris Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$3.75
Ticker SymbolACRS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees69
CountyUSA
Market Cap$469.8M
EBIDTA-74.0M
10-Day Moving Average3.52
P/E Ratio-6.92
20-Day Moving Average3.34
Forward P/E Ratio0.00
50-Day Moving Average3.36
Earnings per Share-0.53
200-Day Moving Average2.38
Profit Margin-1,528.57%
RSI57.02
Shares Outstanding121.1M
ATR0.27
52-Week High4.89
Volume1,495,128
52-Week Low1.05
Most Recent Support Level3.36
Book Value103.1M
Most Recent Resistance Level3.94
P/B Ratio4.36
Upper Keltner3.95
P/S Ratio57.37
Lower Keltner2.73
Debt-to-Equity Ratio3.95
Next Earnings Date05/07/2026
Cash Surplus-8.7M
Next Ex-Dividend DateUnknown

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics Inc In Our Stock Scanner

As of Mar 19, 2026
example chart graphic
Scan Name: Undervalued Blue ChipsScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.